Stay updated on Dolutegravir Study in Completing IMPAACT Participants Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir Study in Completing IMPAACT Participants Clinical Trial page.

Latest updates to the Dolutegravir Study in Completing IMPAACT Participants Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive changes to study content or functionality observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page now includes updated results information (Results First Posted 2026-02-05, Results First Submitted 2026-01-14, and related QC–posted results) and new/updated study documents (Study Protocol and SAP) to accompany the study record.SummaryDifference2%

- Check41 days agoChange DetectedSite revision updated from v3.3.3 to v3.3.4 with no observable impact on content or functionality.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded 'Results Submitted' status and a new 'Locations' section listing California, Florida, and Tennessee, replacing the previous state-location headings; the page now shows Revision: v3.3.3.SummaryDifference0.4%

- Check91 days agoChange DetectedThe page now shows a new revision label (v3.3.2) and removes the previous label (v3.2.0). This appears to be a minor version update with no visible changes to core study content or user actions, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check99 days agoChange DetectedA government funding/operating status notice was removed from the page. The core study information remains unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Dolutegravir Study in Completing IMPAACT Participants Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir Study in Completing IMPAACT Participants Clinical Trial page.